Dendreon Corporation (NASDAQ: DNDN)- Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Its advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic, castrate-resistant, (also known as androgen-independent or hormone-refractory) prostate cancer. Competitors- Agenus Inc (AGEN), Celldex Therapeutics (CLDX), Tengion (TNGN)
Infospace Inc. (NASDAQ: INSP)- InfoSpace, Inc. (InfoSpace) develops search tools and technologies that assist consumers with finding content and information on the Internet. The Company offers search services that enable Internet users to locate and view content, information, merchants, individuals, and products online. InfoSpace offers search services, through its own Websites, such as Dogpile.com, WebCrawler.com, MetaCrawler.com, and WebFetch.com, as well as through the Websites of distribution partners. Competitors- Google Inc (GOOG), Yahoo! Inc (YHOO), Baidu.com (BIDU)
Molycorp Inc. (NYSE: MCP)- Molycorp, Inc. is the only REO producer in the Western Hemisphere and currently produces more than 3,000 metric tons of commercial rare earth materials per year. In addition to its rare earth mine and processing facility at Mountain Pass, California, Molycorp also owns a controlling interest in the Estonia-based Molycorp Silmet AS, which has a production capacity of 3,000 metric tons of rare earth products and 700 metric tons of rare metal products annually and is one of the largest rare metal and rare earth metal producers in Europe. Competitors- Avalon Rare Metals Inc (AVL), 3M Company (MMM), PolyMet Mining Corp (PLM)
SIRIUS XM Radio Inc. (NASDAQ: SIRI)- Sirius XM Radio is set to report their earnings for the first quarter on May 3rd, Tuesday. Analysts are expecting around 220,000 subscriber additions, revenue of around 725 million, and earnings of .01 cent per share. Based on EBITDA guidance of 715 million from the company, we would expect around 150 million for Q1, based on how past years have broken down total year EBITDA numbers. Competitors- Westwood One Inc. (WWON), Cumulus Media Inc (CMLS), Entercom Communications Corp. (ETM)
Vical Inc. (NASDAQ: VICL)- Vical Inc. is expected to gain for benefiting cancer treatment as well,
View the Original article
0 comments
Post a Comment